I
105TH CONGRESS
1ST SESSION
H. R. 2407
To reauthorize the Office of National Drug Control Policy, and for other
purposes.
IN THE HOUSE OF REPRESENTATIVES
SEPTEMBER 4, 1997
Mr. LEVIN (for himself, Mr. RAMSTAD, Mr. BARRETT of Wisconsin, Mr.
LATHAM, Mr. RANGEL, Mr. BLAGOJEVICH, and Mr. CUMMINGS) intro-
duced the following bill; which was referred to the Committee on Govern-
ment Reform and Oversight, and in addition to the Committee on Com-
merce, for a period to be subsequently determined by the Speaker, in
each case for consideration of such provisions as fall within the jurisdic-
tion of the committee concerned
A BILL
To reauthorize the Office of National Drug Control Policy,
and for other purposes.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE AND REFERENCE.
(a) SHORT TITLE.—This Act may be cited as the
‘‘Office of National Drug Control Policy Reauthorization
Act of 1997’’.
(b) REFERENCE.—Whenever in this Act an amend-
ment or repeal is expressed in terms of an amendment
to, or repeal of, a section or other provision, the reference
shall be considered to be made to a section or other provi-
sion of the National Narcotics Leadership Act of 1988.
SEC. 2. REAUTHORIZATION OF OFFICE OF NATIONAL DRUG
CONTROL POLICY.
(a) DEFINITIONS.—
(1) Section 1010 (21 U.S.C. 1507) is placed be-
fore section 1002, is redesignated as section 1001A,
and the heading for the section is amended to read
as follows:
‘‘SEC. 1001A. DEFINITIONS.’’.
(2) Section 1001A, as redesignated, is amend-
ed—
(A) 
by 
redesignating 
paragraphs 
(5)
through (8) as paragraphs (7) through (10), re-
spectively;
(B) 
by 
redesignating 
paragraphs 
(2)
through (4) as paragraphs (3) through (5), re-
spectively;
(C) by striking paragraph (1) and insert-
ing the following:
‘‘(1) the term ‘Office’ means the Office of Na-
tional Drug Control Policy;
‘‘(2) the term ‘drug’ has the same meaning as
the term controlled substance has in section 102(6)
of the Controlled Substances Act (21 U.S.C.
802(6));
(D) in paragraph (3), as redesignated, by
inserting ‘‘, including activities to reduce the
underage use of tobacco or alcoholic beverages’’
after ‘‘demand reduction’’;
(E) in paragraph (4), as redesignated—
(i) by striking ‘‘enforcement’’ after
‘‘any’’;
(ii) by striking ‘‘supply’’ and inserting
‘‘availability’’ after ‘‘reduce the’’; and
(iii) in subparagraph (B) striking ‘‘en-
forcement’’ after ‘‘drug’’;
(F) in paragraph (5), as redesignated—
(i) by striking ‘‘demand for’’ and in-
serting ‘‘use of’’ before ‘‘drugs’’;
(ii) by inserting ‘‘drug abuse’’ after
‘‘including’’;
(iii) in subparagraph (A), by striking
‘‘drug abuse’’;
(iv) in subparagraph (D), by striking
‘‘and’’ at the end;
(v) by adding at the end the following:
‘‘(F) drug-free workplace programs; and’’;
and
(vi) by adding at the end the follow-
ing:
‘‘(G) drug testing;’’;
(G) by inserting after paragraph (5), as re-
designated, the following:
‘‘(6) the term ‘intergovernmental relations’
means domestic activities conducted by a National
Drug Control Program agency that are intended to
reduce the availability and use of drugs, including—
‘‘(A) coordination and facilitation of Fed-
eral, State, and local law enforcement drug con-
trol efforts;
‘‘(B) promotion of coordination and co-
operation among the drug supply reduction and
demand reduction agencies of the various
States, territories, and units of local govern-
ment; and
‘‘(C) such other cooperative governmental
activities which promote a comprehensive ap-
proach to drug control at the National, State,
territory, and local levels.’’; and
(H) in paragraph (10), as redesignated,
by—
(i) inserting ‘‘and ‘Strategy’ ’’ after
‘‘National Drug Control Strategy’’;
(ii) by striking ‘‘means’’ and inserting
‘‘mean’’; and
(iii) striking ‘‘a’’ and inserting ‘‘the’’
after ‘‘means’’.
(b) ESTABLISHMENT
OF
OFFICE
OF
NATIONAL
DRUG
CONTROL
POLICY.—Section 1002 (21 U.S.C.
1501) is amended—
(1) by amending subsection (a) to read as fol-
lows:
‘‘(a) ESTABLISHMENT OF OFFICE.—There is estab-
lished in the Executive Office of the President the ‘‘Office
of National Drug Control Policy’’ that—
‘‘(1) develops national drug control policy;
‘‘(2) coordinates and oversees its implementa-
tion;
‘‘(3) assesses and certifies the adequacy of na-
tional drug control programs and budgets; and
‘‘(4) evaluates their effectiveness.’’;
(2) by amending subsection (b) to read as fol-
lows:
‘‘(b) DIRECTOR AND DEPUTY DIRECTORS.—
‘‘(1) There shall be at the head of the Office of
National Drug Control Policy a Director of National
Drug Control Policy.
‘‘(2) There shall be in the Office of National
Drug Control Policy a Deputy Director of National
Drug Control Policy, who shall assist the Director in
carrying out the responsibilities of the Director
under this Act.
‘‘(3) There shall be in the Office of National
Drug Control Policy a—
‘‘(A) Deputy Director for International
Drug Policy, who shall be responsible for the
activities described in subparagraphs (A), (B),
and (C) of section 1001A(4);
‘‘(B) Deputy Director for Demand Reduc-
tion Policy, who shall be responsible for the ac-
tivities described in section 1001A(5); and
‘‘(C) Deputy Director for Intergovern-
mental Relations, who shall be responsible for
the activities described in paragraphs (4)(D)
and (6) of section 1001A.’’;
(3) by striking subsection (c) and redesignating
subsection (d) as subsection (c); and
(4) by adding at the end the following:
‘‘(d) OFFICE OF NATIONAL DRUG CONTROL POLICY
GIFT FUND.—There is established in the Treasury a fund
for the receipt of gifts, both real and personal, for the
purpose of aiding or facilitating the work of the Office
under section 1003(c). The Office is authorized to accept,
hold, administer, and, solely to encourage funding for con-
ferences, solicit contributions to the fund. Amounts depos-
ited in the fund are authorized to be appropriated, to re-
main available until expended for authorized purposes at
the discretion of the Director. The Director is required
to establish written rules setting forth the criteria to be
used in determining whether the solicitation and accept-
ance of real and personal gifts pursuant to this subsection
would reflect unfavorably upon the ability of the Office
of National Drug Control Policy or any employee to carry
out its responsibilities or official duties in a fair and objec-
tive manner, or would compromise the integrity, or the
appearance of the integrity, of its programs or of any offi-
cial involved in those programs.’’.
(c) APPOINTMENT AND DUTIES OF DIRECTOR AND
DEPUTY DIRECTORS.—Section 1003 (21 U.S.C. 1502) is
amended—
(1) by amending the section heading to read as
follows:
‘‘SEC. 1003. APPOINTMENT AND DUTIES OF DIRECTOR AND
DEPUTY DIRECTORS.’’;
(2) in subsection (a)—
(A) in paragraph (1)—
(i) by inserting ‘‘the Deputy Director’’
after ‘‘The Director,’’;
(ii) by inserting ‘‘Policy’’ after ‘‘De-
mand Reduction’’;
(iii) by striking ‘‘Deputy Director for
Supply Reduction’’ and inserting ‘‘Deputy
Director for International Drug Policy’’;
and
(iv) by striking ‘‘Associate Deputy Di-
rector for National Drug Control Policy’’
and inserting ‘‘Deputy Director for Inter-
governmental Relations’’;
(B) by redesignating paragraphs (3) and
(4) as paragraphs (5) and (6), respectively, and
redesignating paragraph (2) as paragraph (4);
and
(C) by inserting after paragraph (1) the
following:
‘‘(2) The Deputy Director shall—
‘‘(A) carry out the duties and powers prescribed
by the Director; and
‘‘(B) serve as the Director in the absence of the
Director or during any period in which the office of
the Director is vacant.
‘‘(3) In the absence of the Deputy Director, or if the
office of the Deputy Director is vacant, the Director shall
designate such other officer of the Office to serve as the
Director if the Director is absent or unable to serve.’’;
(D) in paragraph (4), as redesignated by—
(i) inserting ‘‘the Deputy Director,’’
after ‘‘The Director’’;
(ii) inserting ‘‘Policy’’ after ‘‘Demand
Reduction’’;
(iii) striking ‘‘Deputy Director for
Supply Reduction’’ and inserting ‘‘Deputy
Director for International Drug Policy’’;
(iv) striking ‘‘Associate Deputy Direc-
tor for National Drug Control Policy’’ and
inserting ‘‘Deputy Director for Intergov-
ernmental Relations’’;
(iv) striking ‘‘Director, a Deputy Di-
rector’’ and inserting ‘‘Director or a Dep-
uty Director’’; and
(v) striking ‘‘, or Associate Director’’;
and
(E) in paragraph (6) as redesignated:
(i) by redesignating subparagraph (B)
as subparagraph (C);
(ii) by inserting after subparagraph
(A) the following:
‘‘(B) Section 5313 of title 5, United States Code, is
amended by adding at the end ‘Deputy Director of Na-
tional Drug Control Policy’.;
(iii) in subparagraph (C), as so redes-
ignated, by adding ‘‘Policy’’ after ‘‘Deputy
Director for Demand Reduction’’ and by
striking ‘‘Supply Reduction’’ and inserting
‘‘International Drug Policy’’ after ‘‘Deputy
Director for’’;
(iv) by inserting after subparagraph
(C), as so redesignated, the following:
‘‘(D) Section 5314 of title 5, United States Code, is
amended by inserting ‘Deputy Director for Intergovern-
mental Relations, Office of National Drug Control Policy’
after ‘Administrator, Office of Information and Regu-
latory Affairs, Office of Management and Budget’;
(v) by striking subparagraph C; and
(F) by adding at the end the following:
‘‘(7) A Federal officer in the Office of National Drug
Control Policy who is appointed by the President, by and
with the advice and consent of the Senate, may not partici-
pate in Federal election campaign activities, except that
such official is not prohibited by this subsection from mak-
ing contributions to individual candidates.’’.
(3) in subsection (b)—
(A) in paragraph (1), by inserting ‘‘goals,’’
before ‘‘objectives’’;
(B) by striking paragraph (2) and insert-
ing the following:
‘‘(2) promulgate the National Drug Control
Strategy and annual Strategy Report in accordance
with section 1005;’’;
(C) in paragraph (3) by adding ‘‘goals,’’
after ‘‘policies,’’;
(D) in paragraph (4)(B) by inserting
‘‘goals,’’ after ‘‘the policies,’’;
(E) in paragraph (5), by inserting ‘‘the
formulation and implementation of National
Drug Control Policy and’’ after ‘‘respect to’’;
and
(F) in paragraph (8)—
(i) by striking ‘‘second following fiscal
year’’ and inserting ‘‘next budget year
scheduled for formulation under the Budg-
et and Accounting Act of 1921 and each of
the 4 subsequent fiscal years,’’; and
(ii) by striking ‘‘annual’’; and
(4) in subsection (c)—
(A) in paragraph (1)—
(i) by striking ‘‘transmit’’ and insert-
ing ‘‘submit’’ after ‘‘shall’’;
(ii) by striking ‘‘and’’ the last place it
appears and inserting ‘‘prior to submis-
sion’’ after ‘‘President’’;
(B) by amending paragraph (2) to read as
follows:
‘‘(2)(A) Each Federal Government program man-
ager, agency head, and department head with responsibil-
ities under the National Drug Control Strategy shall
transmit the drug control budget request of the agency
or department to the Director at the same time as such
request is submitted to their superiors (and before submis-
sion to the Office of Management and Budget) in the
preparation of the budget of the President submitted to
Congress under section 1105(a) of title 31, United States
Code.
‘‘(B) The Director shall request the head of a depart-
ment or agency to include in the department’s or agency’s
budget submission to the Office of Management and
Budget funding requests for specific initiatives that are
consistent with the President s priorities for the National
Drug Control Strategy and certifications made pursuant
to paragraph (3), and the head of the department or agen-
cy shall comply with such a request.
‘‘(C) The head of each National Drug Control Pro-
gram agency shall ensure timely development and submis-
sion to the Director of drug control budget requests trans-
mitted pursuant to subsection (c)(2), in such format as
may be designated by the Director with the concurrence
of the Director of the Office of Management and Budg-
et.’’.
(C) in paragraph (3)—
(i) in subparagraph (B), by striking
‘‘and’’ after ‘‘adequate’’ the last place it
appears;
(ii) in subparagraph (C), by striking
the period and inserting ‘‘; and’’;
(D) by redesignating paragraph (4) as sub-
paragraph (D) and striking ‘‘the Director
shall’’;
(E) by striking paragraphs (5), (7), and
(8), and redesignating paragraph (6) as para-
graph (4); and
(F) in paragraph (4), as redesignated, by
adding at the end the following:
‘‘(C) The Director shall annually submit to Congress
a report describing the approval of any reprogramming or
transfer of appropriated funds pursuant to this section.’’;
(5) in subsection (d)—
(A) in paragraph (1), by striking ‘‘up to
75 and such additional’’ and inserting ‘‘such’’;
(B) in paragraph (5)—
(i) by striking ‘‘accept and use’’ and
inserting ‘‘accept, use, and solicit’’;
(ii) by inserting ‘‘and gifts’’ after
‘‘property’’; and
(iii) by inserting ‘‘, and the private
sector, as authorized in section 1002(d)’’
before the semicolon;
(C) in paragraph (7)—
(i) in subparagraph (A), by striking
‘‘and’’ at the end; and
(ii) in subparagraph (B), by adding
‘‘and’’ at the end; and
(iii) by adding at the end the follow-
ing:
‘‘(C) commission special studies and re-
ports by a National Drug Control Program
agency, with the concurrence of the head of the
affected agency;’’; and
(D) by striking paragraphs (8) and (9)
and inserting the following:
‘‘(8) except to the extent that the Director’s au-
thority under this paragraph is limited in an annual
appropriations Act, and with the concurrence of the
head of the affected agency and upon advance notice
to the Committees of Appropriations of each House
of Congress, transfer funds appropriated to a Na-
tional Drug Control Program agency program, activ-
ity, or function designated by the Director pursuant
to subsection (c) to a different National Drug Con-
trol Program agency program, activity, or function
designated by the Director pursuant to subsection
(c) in an amount that does not exceed 2 percent of
the amount appropriated to either program, activity,
or function;
‘‘(9) issue to the head of a National Drug Con-
trol Program agency a funds control notice described
in subsection (f) to ensure compliance with the Na-
tional Drug Control Program; and
‘‘(10) participate in the drug certification proc-
ess pursuant to section 490 of the Foreign Assist-
ance Act of 1961 (22 U.S.C. 2291j).’’;
(6) by striking the second subsection designated
as subsection (f).
(d) COORDINATION WITH EXECUTIVE BRANCH DE-
PARTMENTS AND AGENCIES.—Section 1004 (21 U.S.C.
1503) is amended—
(1) by amending the section heading to read as
follows:
‘‘SEC. 1004. COORDINATION WITH EXECUTIVE BRANCH DE-
PARTMENTS AND AGENCIES IN SUPPLY RE-
DUCTION, DEMAND REDUCTION, AND INTER-
GOVERNMENTAL RELATIONS.’’;
(2) in subsection (a)(1)—
(A) by inserting ‘‘cooperate with and’’ be-
fore ‘‘provide’’; and
(B) by inserting ‘‘and the annual report to
Congress’’ before the period.
(e) DEVELOPMENT AND SUBMISSION OF NATIONAL
DRUG CONTROL STRATEGY.—Section 1005 (21 U.S.C.
1504) is amended to read as follows:
‘‘SEC. 1005. DEVELOPMENT, SUBMISSION, IMPLEMENTA-
TION, AND ASSESSMENT OF NATIONAL DRUG
CONTROL STRATEGY.
‘‘(a) TIMING, CONTENT, AND PROCESS FOR DEVEL-
OPMENT AND SUBMISSION OF THE NATIONAL DRUG CON-
TROL STRATEGY.—
‘‘(1) Not later than February 1, 1997, the
President shall submit to the Congress a National
Drug Control Strategy, which shall set forth a com-
prehensive 10-year plan for reducing drug abuse and
its consequences in the United States by limiting the
availability of and reducing the demand for illegal
drugs. Any part of such strategy that involves infor-
mation properly classified under criteria established
by an Executive order shall be presented to Congress
separately from the rest of the strategy.
‘‘(2) The National Drug Control Strategy sub-
mitted under paragraph (1) shall include—
‘‘(A) comprehensive, research-based, long-
range goals for reducing drug abuse and the
consequences of drug abuse in the United
States;
‘‘(B) measurable objectives to accomplish
long-term goals;
‘‘(C) 5-year projections for program and
budget priorities; and
‘‘(D) a review of State, local, and private
sector drug control activities to ensure that the
United States pursues well-coordinated and ef-
fective drug control at all levels of government.
‘‘(3) CONSULTATIONS.—
‘‘(A) In developing and effectively imple-
menting the National Drug Control Strategy,
the Director shall consult with—
‘‘(i) the heads of the National Drug
Control Program agencies;
‘‘(ii) Congress;
‘‘(iii) State and local officials;
‘‘(iv) private citizens and organiza-
tions with experience and expertise in de-
mand reduction; and
‘‘(v) private citizens and organizations
with experience and expertise in supply re-
duction;
‘‘(B) The National Drug Control Strategy
and each annual Strategy Report shall indicate
the persons consulted under this paragraph.
‘‘(b) ANNUAL STRATEGY REPORT.—Not later than
February 1, 1998, and on February 1 of each year there-
after, the President shall submit to Congress an annual
report on the progress in implementing the Strategy under
subsection (a), which shall include—
‘‘(1) an assessment of the Federal effectiveness
in achieving the Strategy goals and objectives using
the performance measurement system described in
subsection (c);
‘‘(2) any modifications of the Strategy;
‘‘(3) an assessment of how the budget proposal
submitted 
under 
section 
1003(c) 
(21 
U.S.C.
1502(c)) is intended to implement the strategy and
whether the funding levels contained in such pro-
posal are sufficient to implement such strategy;
‘‘(4) an assessment of current drug use and
availability, impact of drug use, and treatment avail-
ability. This assessment will include—
‘‘(A) estimates of drug prevalence and fre-
quency of use as measured by national, State,
and local surveys of illicit drug use and by
other special studies of—
‘‘(i) casual and chronic drug use;
‘‘(ii) high-risk populations, including
school dropouts, the homeless and tran-
sient, arrestees, parolees, probationers, and
juvenile delinquents; and
‘‘(iii) drug use in the workplace and
the productivity lost by such use;
‘‘(B) an assessment of the reduction of
drug availability against an ascertained base-
line, as measured by—
‘‘(i) the quantities of cocaine, heroin,
marijuana, methamphetamine, and other
drugs available for consumption in the
United States;
‘‘(ii) the amount of marijuana, co-
caine, and heroin entering the United
States;
‘‘(iii) the number of hectares of mari-
juana, poppy, and coca cultivated and de-
stroyed;
‘‘(iv) the number of metric tons of
marijuana, heroin, and cocaine seized;
‘‘(v) the number of cocaine and meth-
amphetamine processing laboratories de-
stroyed;
‘‘(vi) changes in the price and purity
of heroin and cocaine;
‘‘(vii) the amount and type of con-
trolled substances diverted from legitimate
retail and wholesale sources; and
‘‘(viii) the effectiveness of Federal
technology programs at improving drug de-
tection capabilities in interdiction, and at
United States ports of entry;
‘‘(C) an assessment of the reduction of the
consequences of drug use and availability, which
shall include estimation of—
‘‘(i) burdens drug users placed on
hospital emergency departments in the
United States, such as the quantity of
drug-related services provided;
‘‘(ii) the annual national health care
costs of drug use, including costs associ-
ated with people becoming infected with
the human immuno-deficiency virus and
other infectious diseases as a result of
drug use;
‘‘(iii) the extent of drug-related crime
and criminal activity; and
‘‘(iv) the contribution of drugs to the
underground economy, as measured by the
retail value of drugs sold in the United
States;
‘‘(D) a determination of the status of drug
treatment in the United States, by assessing—
‘‘(i) public and private treatment ca-
pacity within each State, including infor-
mation on the treatment capacity available
in relation to the capacity actually used;
‘‘(ii) the extent, within each State, to
which treatment is available;
‘‘(iii) the number of drug users the
Director estimates could benefit from
treatment; and
‘‘(iv) the specific factors that restrict
the availability of treatment services to
those seeking it and proposed administra-
tive or legislative remedies to make treat-
ment available to those individuals;
‘‘(E) a review of the research agenda of
the Counter-Drug Technology Assessment Cen-
ter to reduce the availability and abuse of
drugs;
‘‘(5) an assessment of private sector initiatives
and cooperative efforts between the Federal Govern-
ment and State and local governments for drug con-
trol.
‘‘(c) PERFORMANCE MEASUREMENT SYSTEM.—The
Director shall include with the annual Strategy Report a
description of the national drug control performance
measurement system, designed in consultation with af-
fected National Drug Control Program agencies, that—
‘‘(1) develops performance objectives, measures,
and targets for each National Drug Control Strategy
goal and objective;
‘‘(2) revises performance objectives, targets,
and measures to conform with National Drug Con-
trol Program Agency budgets;
‘‘(3) identifies major programs and activities of
the National Drug Control Program Agencies that
support the goals and objectives of the National
Drug Control Strategy;
‘‘(4) evaluates implementation of major pro-
gram activities supporting the National Drug Con-
trol Strategy developed under this section;
‘‘(5) monitors consistency between the drug-re-
lated goals and objectives of the National Drug Con-
trol Program agencies and ensures that drug control
agency goals and budgets support and are fully con-
sistent with the National Drug Control Strategy;
and
‘‘(6) coordinates the development and imple-
mentation of national drug control data collection
and reporting systems to support policy formulation
and performance measurement, including—
‘‘(A) an assessment of the quality of cur-
rent drug use measurement instruments and
techniques to measure supply reduction and de-
mand reduction activities;
‘‘(B) an assessment of the adequacy of the
coverage of existing national drug use measure-
ment instruments and techniques to measure
the casual drug user population and groups
that are at risk for drug use; and
‘‘(C) an assessment of the actions the Di-
rector shall take to correct any deficiencies and
limitations identified pursuant to subpara-
graphs (A) and (B) of subsection (b)(4).’’.
(f) HIGH INTENSITY DRUG TRAFFICKING AREAS
PROGRAM.—The National Narcotics Leadership Act of
1988 is amended by inserting after section 1005 the fol-
lowing:
‘‘SEC. 1005A. HIGH INTENSITY DRUG TRAFFICKING AREAS
PROGRAM.
‘‘(a) There is established in the Office a program to
be known as the ‘High Intensity Drug Trafficking Areas
Program’.
‘‘(b) The Director, upon consultation with the Attor-
ney General, the Secretary of the Treasury, the Secretary
of Health and Human Services, heads of the National
Drug Control Program agencies, and the Governors of
each State, may designate any specified area of the United
States as a high intensity drug trafficking area. After
making such a designation and in order to provide Federal
assistance to the area so designated, the Director may—
‘‘(1) obligate such sums as appropriated for the
High Intensity Drug Trafficking Area Program;
‘‘(2) direct the temporary reassignment of Fed-
eral personnel to such area, subject to the approval
of the Secretary of the department or head of the
agency that employs such personnel;
‘‘(3) take any other action authorized under
section 1003 to provide increased Federal assistance
to such areas;
‘‘(4) coordinate actions under this paragraph
with State and local officials; and
‘‘(5) in consultation with affected National
Drug Control Policy agencies, promulgate such regu-
lations for the effective implementation of the High
Intensity Drug Trafficking Areas Program.
‘‘(c) When considering the designation of an area
underthis section as a high intensity drug trafficking area,
the Director shall consider, in addition to such other cri-
teria as the Director considers to be appropriate, the ex-
tent to which—
‘‘(1) the area is a center of illegal drug produc-
tion, manufacturing, importation, or distribution;
‘‘(2) State and local law enforcement agencies
have committed resources to respond to the drug
trafficking problem in the area, thereby indicating a
determination to respond aggressively to the prob-
lem;
‘‘(3) State and local demand reduction agencies
have committed resources to respond to drug abuse
in the area, thereby indicating a determination to re-
spond to the problem;
‘‘(4) drug-related activities in the area are hav-
ing a harmful impact in other areas of the country;
and
‘‘(5) a significant increase in allocation of Fed-
eral resources is necessary to respond adequately to
drug-related activities in the area.’’.
(g) COUNTER-DRUG
TECHNOLOGY
ASSESSMENT
CENTER.—Section 1008 (21 U.S.C. 1505) is amended to
read as follows:
‘‘SEC. 1008. COUNTER-DRUG TECHNOLOGY ASSESSMENT
CENTER.
‘‘(a) ESTABLISHMENT.—There is established within
the Office the Counter-Drug Technology Assessment Cen-
ter (in this section referred to as the ‘Center’). The Center
shall operate under the authority of the Director of Na-
tional Drug Control Policy and shall serve as the central
counter-drug technology research and development organi-
zation of the United States Government.
‘‘(b) DIRECTOR OF TECHNOLOGY.—There shall be at
the head of the Center the Director of Technology, who
shall be appointed by the Director of National Drug Con-
trol Policy from among individuals qualified and distin-
guished in the area of science, medicine, engineering, or
technology.
‘‘(c) ADDITIONAL RESPONSIBILITIES OF THE DIREC-
TOR OF NATIONAL DRUG CONTROL POLICY.—
‘‘(1) The Director, acting through the Director
of Technology shall—
‘‘(A) identify and define the short-, me-
dium-, and long-term scientific and techno-
logical needs of Federal, State, and local drug
supply reduction agencies, including—
‘‘(i) advanced surveillance, tracking,
and radar imaging;
‘‘(ii) electronic support measures;
‘‘(iii) communications;
‘‘(iv) data fusion, advanced computer
systems, and artificial intelligence; and
‘‘(v) chemical, biological, radiological
(including neutron, electron, and graviton),
and other means of detection;
‘‘(B) identify demand reduction basic and
applied research needs and initiatives, in con-
sultation with affected National Drug Control
Program agencies, including—
‘‘(i) improving treatment through
neuroscientific advances;
‘‘(ii) improving the transfer of bio-
medical research to the clinical setting, and
‘‘(iii) developing new advances in drug
abuse prevention programming;
‘‘(iv) in consultation with the National
Institute on Drug Abuse, and through
interagency agreements or grants, examine
addiction and rehabilitation research and
the application of technology to expanding
the effectiveness or availability of drug
treatment;
‘‘(C) make a priority ranking of such needs
identified in subparagraphs (A) and (B) accord-
ing to fiscal and technological feasibility, as
part of a National Counter-Drug Enforcement
Research and Development Program;
‘‘(D) oversee and coordinate counter-drug
technology initiatives with related activities of
other Federal civilian and military departments;
‘‘(E) provide support to the development
and implementation of the national drug control
performance measurement system; and
‘‘(F) pursuant to the authority of the Di-
rector of National Drug Control Policy under
section 1003 (21 U.S.C. 1502), submit requests
to Congress for the reprogramming or transfer
of funds appropriated for counter-drug tech-
nology research and development.
‘‘(2) The authority granted to the Director
under this section shall not extend to the award of
contracts, management of individual projects, or
other operational activities.
‘‘(d) ASSISTANCE AND SUPPORT TO OFFICE OF NA-
TIONAL DRUG CONTROL POLICY.—The Department of
Defense and the Department of Health and Human Serv-
ices shall, to the fullest extent possible, render assistance
and support to the Office and its Director, in the conduct
of counter-drug technology assessment.’’.
(h) TERMINATION OF OFFICE OF NATIONAL DRUG
CONTROL POLICY.—Section 1009 (42 U.S.C. 1506) is
amended to read as follows:
‘‘SEC. 1009. TERMINATION OF OFFICE OF NATIONAL DRUG
CONTROL POLICY.
‘‘Effective on September 30, 2009, this subtitle and
the amendments made by this subtitle are repealed.’’.
(i) AUTHORIZATION OF APPROPRIATIONS.—Section
1011 (21 U.S.C. 1508) is amended to read as follows:
‘‘SEC. 1011. AUTHORIZATION OF APPROPRIATIONS.
‘‘There are authorized to be appropriated to carry out
this subtitle, to remain available until expended, such
sums as may be necessary for each of the fiscal years
1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006,
2007, 2008, and 2009.’’.
(j) ESTABLISHMENT
OF
SPECIAL
FORFEITURE
FUND.—Section 6073 of the Asset Forfeiture Amend-
ments Act of 1988 (21 U.S.C. 1509) is amended—
(1) in subsection (b),
(A) by striking ‘‘section 524(c)(9)’’ and in-
serting ‘‘section 524(c)(8)’’;
(B) by striking ‘‘section 9307(g)’’ and in-
serting ‘‘section 9703(g)’’; and
(2) in subsection (e), by striking ‘‘strategy’’ and
inserting ‘‘Strategy’’.
Æ